{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:50:40Z","timestamp":1768283440073,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007072","name":"Amgen Inc. | Onyx Pharmaceuticals","doi-asserted-by":"publisher","award":["ISS 20159882"],"award-info":[{"award-number":["ISS 20159882"]}],"id":[{"id":"10.13039\/100007072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007072","name":"Amgen Inc. | Onyx Pharmaceuticals","doi-asserted-by":"publisher","award":["ISS 20159882"],"award-info":[{"award-number":["ISS 20159882"]}],"id":[{"id":"10.13039\/100007072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007072","name":"Amgen Inc. | Onyx Pharmaceuticals","doi-asserted-by":"publisher","award":["ISS 20159882"],"award-info":[{"award-number":["ISS 20159882"]}],"id":[{"id":"10.13039\/100007072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-021-00544-x","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T19:02:45Z","timestamp":1630695765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9039-3474","authenticated-orcid":false,"given":"Yunxin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathish Kumar","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehena","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Hui","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8033-5024","authenticated-orcid":false,"given":"Nicholas","family":"Grigoropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-6975","authenticated-orcid":false,"given":"Shin Yeu","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingge","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"SGHMM1 Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ee Mei","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh Shan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Phipps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Lorraine W. Y.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-0997","authenticated-orcid":false,"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-2226","authenticated-orcid":false,"given":"Chandramouli","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"544_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000-14. Leukemia. 2017;31:1915\u201321.","journal-title":"Leukemia"},{"key":"544_CR2","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"544_CR3","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801\u20139.","journal-title":"Blood"},{"key":"544_CR4","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"JJ Lahuerta","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB, Cord\u00f3n L, Cedena MT, Puig N, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM Clinical Trials. J Clin Oncol. 2017;35:2900\u201310.","journal-title":"J Clin Oncol"},{"key":"544_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338.","journal-title":"Lancet Oncol"},{"key":"544_CR6","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1038\/leu.2017.122","volume":"31","author":"P Hari","year":"2017","unstructured":"Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, et al. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. 2017;31:2630\u201341.","journal-title":"Leukemia"},{"key":"544_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/leu.2017.327","volume":"32","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, D\u2019Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, et al. Phase 1\/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018;32:979\u201385.","journal-title":"Leukemia"},{"key":"544_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3324\/haematol.2019.243428","volume":"106","author":"R Mina","year":"2020","unstructured":"Mina R, Bonello F, Petrucci MT, Liberati AM, Conticello C, Ballanti S, et al. Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. Haematologica. 2020;106:1079\u20131085.","journal-title":"Haematologica"},{"key":"544_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2018-99-112093","volume":"132","author":"F Gay","year":"2018","unstructured":"Gay F, Cerrato C, Rota Scalabrini D, Galli M, Belotti A, Zamagni E, et al. Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 Cycles Vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation: analysis of the randomized forte trial in newly diagnosed multiple myeloma (NDMM). Blood. 2018;132:121\u2013121.","journal-title":"Blood"},{"key":"544_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero J, de Tute R, Paiva B, Perez JJ, B\u00f6ttcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytom B Clin Cytom. 2016;90:61\u201372.","journal-title":"Cytom B Clin Cytom"},{"key":"544_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519\u201327.","journal-title":"Lancet"},{"key":"544_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393:253\u201364.","journal-title":"Lancet"},{"key":"544_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","volume":"124","author":"S Bringhen","year":"2014","unstructured":"Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124:63\u201369.","journal-title":"Blood"},{"key":"544_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2018-99-112796","volume":"132","author":"T Maeda","year":"2018","unstructured":"Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I. Carfilzomib versus bortezomib in combination with cyclophosphamide and dexamethasone for treatment of first relapse or primary refractory multiple myeloma (MM): outcomes based on genetic risk and long term follow up of the Phase 2 Muk Five Study. Blood. 2018;132:306\u2013306.","journal-title":"Blood"},{"key":"544_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269\u201377.","journal-title":"Leukemia"},{"key":"544_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.62","volume":"6","author":"Y Chen","year":"2016","unstructured":"Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, et al. Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Blood Cancer J. 2016;6:e450.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00544-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:23:06Z","timestamp":1669918986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00544-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00544-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"18 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.C., S.G. and C.N. report grants from Amgen during the conduct of the study. W.J.C. reports grants from Celgene, Janssen, ASLAN. Y.C., W.J.C., C.N. reports personal fees from Amgen, Janssen, BMS. W.J.C. reports personal fees from Abbvie, Novartis, Kyan. C.N. reports personal fees for Abbvie, Astra Zeneca, and Takeda. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}